SAVE THE DATE - APRIL 2-6, 2018

2017 Programs 

APRIL 24 - APRIL 25

	Inflammation Inhibitors
	Protein-Protein Interactions, Part 1
	GPCR-Targeted Drug Design
	Blood-Brain Penetrant Inhibitors

2017 SYMPOSIA APRIL 27

	Biophysical Approaches for Drug Discovery
	Small Molecules for Cancer Immunotherapy

2017 PLENARY KEYNOTES

PROTACs: Inducing Protein Degradation as a Therapeutic Strategy

Craig M. Crews, Ph.D., Yale University

Drug Discovery and Pan-Assay Interference Compounds (PAINS)

Jonathan B. Baell, Ph.D., Monash University

ABOUT THE 2017 EVENT

700 high-level participants from 29 countries convened in San Diego for Cambridge Healthtech Institute's 12th Annual Drug Discovery Chemistry. 23% of attendees were from Big Pharma, 48% from Biotech, and 17% from Academia. 41% were Scientists/Technologists, 28% were Executives/Director, and 11% were Professors. Focused on discovery and optimization challenges of small molecule drug candidates, this event provided many exciting opportunities for scientists to create a unique program to hear presentations most suited to one's personal interests by going back and forth among concurrent meeting tracks. New for 2017 was the addition of a Part 2 to the always popular Protein-Protein Interactions, a track on GPCR-Targeted Drug Design, and a symposium on Small Molecules for Cancer Immunotherapy. Upgrading to the Hilton Bayfront next year, Drug Discovery Chemistry 2018 will return to San Diego from April 2-6, 2018.

2017 EVENT FEATURES

• More than 140 presentations
• 700+ high-level participants
• 70+ posters
• Interactive roundtable, breakout & panel discussions
• “Track-hop” between concurrent meetings
• Exclusive exhibit & poster viewing hours
• Dedicated networking opportunities